Voriconazole (API): Global Market Growth Study Report

Introduction

Voriconazole widely known as VFEND is a synthetic antifungal second generation broad spectrum triazole derivative of flucanozole drug which shows action by inhibiting CYP P450 (cytochrome P450) dependent enzyme 14-alpha sterol demethylase present in fungal cell membrane causing disruption and resulting in fungal growth hindrance.

Voriconazole antifungal drug developed in 1990’s and approved by FDA in 2002. As per the Volza global exporters and supplier’s directory facts updated till 26 august 2023, there are 670 active voriconazole exporters in world exporting to 1571 buyers. M S MSN Laboratories Pvt, Ltd holds top for export market share with 601 shipments followed by Sandoz private Ltd with 433 and AUROLAB with 390 shipments. Major exporting countries from India are Bangladesh, Japan, Turkey, Brazil, Egypt, Russia, United Arab Emirates, Spain.

Major supplier’s in voriconazole API market from the various resource are: 1. Dr.Reddy’s laboratories 2. Murali Krishna Pharma

3. SGMR Pharmaceutical 4. Glenmark Pharmaceuticals 5. ST Pharma 6. Synergene 7. Rundu Pharmaceutical 8. Zhejiang huahai pharmaceutical 9. Neuland lab

Review of Literature

• Rubio C, et al. [1] summarized by economic analysis that voriconazole is more cost effective compared to other drugs of the same antifungal group given invasively.
• Jeu L, et al. [2] clearly stated about the pharmacokinetic, pharmacodynamic and clinical effectiveness of voriconazole over other antifungal drugs where their resistance is increasing.
• Sabo JA, et al. [3] based on the data search resources stated that treatment of superficial fungal infections to chronic conditions voriconazole shown to be a promising drug alternative among antifungals.

• Hariprasad, et al. [4] reviewed clinical studies and case reports in ophthalmic research publications of the successful treatment of fungal eye infections utilizing voriconazole
• Rathbun, et al. [5] evaluated the review studies regarding the safety and efficacy profile of voriconazole.
• Pearson, et al. [6] studied the data pertaining to voriconazole and comparing with the amphotericin B drug which is highly effective.
• Williams K, et al. [7] discussed the photosensitivity of voriconazole, that if not properly monitored may lead to squamous cell carcinoma stressed the need for further research studies.
• Shi, et al. [8] summarized the studies on population pharmacokinetic models of voriconazole.
• Pires de SA FAP, et al. [9] formulated liposomal delivery systems for voriconazole for treatment of fungal eye infections as ocular systems.
• El-Hadidi GN, et al. [10] formulated microemulsions as a delivery vehicle for voriconazole as the drug is poorly water soluble.
• Pandurangan DK, et al. [11] investigated the formulation of ophthalmic solid lipid nanoparticles in-situ gel voriconazole.
• Asija R, et al. [12] formulated voriconazole ointments for topical delivery.
• Esentruk I, et al. [13] formulated nanofibers of voriconazole for studying its effect against candida species.

Conclusion

The present research study on the market scenario of the Voriconazole API, proves to be promising and the continuous efforts put by the companies for sustenance in the global market worth studying and appreciating the efforts put by the R& D striving for the patient compliance in formulation development for the treatment of deadly fungal infections and strive for early recovery is the motive of the research studies.

Acknowledgements

The authors are thankful to Dr.REDDY’S laboratories and Dr. Jyoshi Reddy for providing the gift sample.